Subscribe
shutterstock_1449295031_oleksandrshnuryk
OleksandrShnuryk / Shutterstock.com
13 December 2021GenericsAlex Baldwin

Pharmavite accuses Bausch, GSK of ‘sham’ patent litigation

Nutritional supplements manufacturer Pharmavite has filed an antitrust suit against Bausch & Lomb and GlaxoSmithKline (GSK), claiming that they are filing sham patent litigation related to its “PreserVision” products

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Bausch settles $300m antitrust case over diabetes drug price hikes
13 September 2021   Canadian pharma firm Bausch Health has agreed to settle an antitrust suit where it was accused of holding an illegal monopoly on the diabetes drug Glumetza.
Americas
Bausch & Lomb looks to protect patents in eyedrop lawsuit
26 October 2021   Bausch & Lomb has accused a Nashville-based ophthalmic company of infringing two patents covering its eye-brightening drops, Lumify.
Americas
GSK to buy Sierra Oncology for $1.9bn
14 April 2022   GlaxoSmithKline has agreed to acquire California-based biopharma company Sierra Oncology for $1.9 billion, in a move that bolsters the UK company’s cancer business.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Big Pharma
Bausch settles $300m antitrust case over diabetes drug price hikes
13 September 2021   Canadian pharma firm Bausch Health has agreed to settle an antitrust suit where it was accused of holding an illegal monopoly on the diabetes drug Glumetza.
Americas
Bausch & Lomb looks to protect patents in eyedrop lawsuit
26 October 2021   Bausch & Lomb has accused a Nashville-based ophthalmic company of infringing two patents covering its eye-brightening drops, Lumify.
Americas
GSK to buy Sierra Oncology for $1.9bn
14 April 2022   GlaxoSmithKline has agreed to acquire California-based biopharma company Sierra Oncology for $1.9 billion, in a move that bolsters the UK company’s cancer business.

More on this story

Big Pharma
Bausch settles $300m antitrust case over diabetes drug price hikes
13 September 2021   Canadian pharma firm Bausch Health has agreed to settle an antitrust suit where it was accused of holding an illegal monopoly on the diabetes drug Glumetza.
Americas
Bausch & Lomb looks to protect patents in eyedrop lawsuit
26 October 2021   Bausch & Lomb has accused a Nashville-based ophthalmic company of infringing two patents covering its eye-brightening drops, Lumify.
Americas
GSK to buy Sierra Oncology for $1.9bn
14 April 2022   GlaxoSmithKline has agreed to acquire California-based biopharma company Sierra Oncology for $1.9 billion, in a move that bolsters the UK company’s cancer business.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York